Medicare Part D and Medicare Advantage plans with prescription drug coverage may cover Xarelto if it appears on the plan’s formulary. There are currently no generic alternatives available for Xarelto, ...

Advisers to the Food and Drug Administration have voted against recommending approval of Johnson & Johnson’s blood-thinner Xarelto as a treatment for patients with acute coronary syndrome. Advisers to ...

The orodispersible film formulation offers new dosing options for preventing clots and treating thrombotic events across ...

WASHINGTON (AP) — A panel of Food and Drug Administration experts again rejected Johnson & Johnson’s bid to expand use of its blood thinner Xarelto to reduce dangerous blood clots in a new group of ...

FRANKFURT (Reuters) - Bayer has initiated two new late-stage studies to widen the use of its anti-blood-clotting pill Xarelto, one of its most important new drugs. The German company, which is ...

The FDA has blocked J&J's (NYSE:JNJ) application to widen the use of its Xarelto blood thinner to prevent heart attacks and strokes in people with acute coronary syndrome, a market estimated at $1B. J ...

Bayer applies for EU approval for use in stroke prevention J&J files new drug application with FDA Companies say filed response to FDA for use after surgery (Adds J&J filing for U.S. approval) ...

This application, submitted as a hybrid application via the EMA's Centralized Procedure, is a generic version of the innovator product Xarelto, from Bayer AG, which is available as oral tablets.